Clinical Review a Practical Approach to the Use of Etanercept

This clinical review outlines a practical approach to the use of etanercept in the treatment of psoriasis. Etanercept is FDA-approved for treatment of adult patients with chronic moderate-to-severe plaque psoriasis and psoriatic arthritis in addition to several other rheumatologic conditions. It is a recombinant fusion protein consisting of tumor necrosis factor-alpha (TNF-α) receptor components covalently linked to the Fc portion of IgG. Etanercept binds and inactivates TNF-α. The most common side effect associated with its use is mild to moderate injection-site reactions that usually do not require discontinuation of treatment. There is also likely some increased risk of infection and malignancy associated with this agent that one should consider when prescribing this medication.

[1]  B. Hutton.  Biologic Treatment of Rheumatoid Arthritis and the Risk of Malignancy: Analyses From a Large US Observational Study , 2009 .

[2]  R. Wallis.  Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. , 2008, The Lancet. Infectious diseases.

[3]  K. Reich,et al.  Tumor necrosis factor antagonists in the therapy of psoriasis. , 2008, Clinics in dermatology.

[4]  M. Lebwohl,et al.  National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. , 2008, Journal of the American Academy of Dermatology.

[5]  Steven R Feldman,et al.  Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.

[6]  F. Kerdel,et al.  From conventional to cutting edge: the new era of biologics in treatment of psoriasis , 2008, Dermatologic therapy.

[7]  G. Rimmelzwaan,et al.  The effect of anti-tumour necrosis factor α treatment on the antibody response to influenza vaccination , 2007, Annals of the rheumatic diseases.

[8]  A. Menter,et al.  Current and future management of psoriasis , 2007, The Lancet.

[9]  A. Gottlieb,et al.  Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. , 2007, Archives of dermatology.

[10]  K. Papp.  The safety of etanercept for the treatment of plaque psoriasis , 2007, Therapeutics and clinical risk management.

[11]  S. Kazi,et al.  The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran’s Affairs patients receiving tumor necrosis factor alpha antagonists , 2007, Rheumatology International.

[12]  D. Furst,et al.  Problems encountered during anti-tumour necrosis factor therapy. , 2006, Best practice & research. Clinical rheumatology.

[13]  P. Merkel,et al.  Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. , 2006, Arthritis and rheumatism.

[14]  J. S. Sánchez Carazo,et al.  Safety of Etanercept in Psoriasis , 2006 .

[15]  J. S. Sánchez Carazo,et al.  Safety of etanercept in psoriasis: a critical review. , 2006, Drug safety.

[16]  J. Hunek,et al.  Etanercept injection site reaction. , 2005, Dermatology nursing.

[17]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[18]  L. Jacobsson,et al.  Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists , 2005, Annals of the rheumatic diseases.

[19]  N. Zein.  Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. , 2005, Journal of hepatology.

[20]  D. Goldsmith,et al.  Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis. , 2005, American journal of clinical dermatology.

[21]  Richard W. Martin,et al.  Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. , 2004, The Journal of rheumatology.

[22]  R S Wallis,et al.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  F. Wolfe,et al.  Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. , 2004, The American journal of medicine.

[24]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[25]  M. Wener,et al.  Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.

[26]  M. Braun,et al.  Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist , 2003, Annals of Internal Medicine.

[27]  M. Greene,et al.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. , 2002, Arthritis and rheumatism.

[28]  R. Day.  Adverse reactions to TNF-α inhibitors in rheumatoid arthritis , 2002, The Lancet.

[29]  Najia Shakoor,et al.  Drug-induced systemic lupus erythematosus associated with etanercept therapy , 2002, The Lancet.

[30]  R. Day.  Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. , 2002, Lancet.

[31]  B. Bozkurt,et al.  Results of Targeted Anti–Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure , 2001, Circulation.

[32]  D. Paty,et al.  TNF neutralization in MS , 1999, Neurology.